Clinical trials: Electric Countershock
Heart Failure
The Effect of an Azygos Vein Coil on Defibrillation Threshold
When implantable cardiac defibrillators are implanted (ICDs), the defibrillation threshold (DFT), of the amount of energy required to effectively terminate life-threatening arrhythmias is determined.
- Trial name
- NCT00798174
- Testing
- Standard configuration vs. azygos coil
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Washington University School of Medicine
Atrial Fibrillation, Atrial Flutter
Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr
Double blind study to assess versus placebo the efficacy of SSR149744C for the conversion of atrial fibrillation/flutter to sinus rhythm at the time of the planned electrical cardioversion.
- Trial name
- CORYFEE (NCT00232310)
- Testing
- CELIVARONE (SSR149744C)
- Where
- 9 sites in United States, Canada and 7 more
- Volunteers
- 150 people
- Sponsor
- Sanofi
Cardiac Event, Sudden Cardiac Death
To Determine Optimal Time for Delivering Electrical Shocks to Cardiac Arrest Patients
In this study, we are comparing the difference in outcomes between patients who were given shocks to the heart, during the upstroke of cardiopulmonary resuscitation (CPR) and before CPR is started.
- Conditions
- Cardiac Event, Sudden Cardiac Death, Death, Ventricular Fibrillation
- Trial name
- NCT01665755
- Testing
- Upstroke Compression Defibrillation, Precompression Defibrillation
- Where
- Singapore
- Volunteers
- 180 people
- Sponsor
- Singapore General Hospital
Tachycardia, Ventricular Arrhythmias
Acute Study to Collect Electrical Signals From the Heart Using a Special Lead
The main purpose of this clinical study is to collect electrograms from an investigational lead placed in an extravascular space, for development of a future Implantable Cardioverter Defibrillator (ICD) system.
- Trial name
- NCT02772380
- Testing
- Defibrillation following induction of VT/VF
- Where
- 36 sites in United States, Australia and 10 more
- Volunteers
- 87 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Atrial Fibrillation
Early Versus Late DC-cardioversion of Persistent Atrial Fibrillation. Effect on Atrial Remodeling,Inflammatory and Neurohumoral Markers and Recurrence of Atrial Fibrillation
Atrial fibrillation (AF) is the most common arrhythmia present in 1% of population under 60 years of age and reaching up to 15% at 80 years.
- Trial name
- NCT01593150
- Testing
- Pradaxa, TEE, Compare TEE guided cardioversion to Dabigatran + DC cardioversion
- Where
- Denmark
- Volunteers
- 141 people
- Sponsor
- Odense University Hospital
Atrial Fibrillation
Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)
This non-interventional prospective study is a post-authorization safety study (PASS) of vernakalant conducted to collect information about normal conditions of use and appropriate dosing, and to quantify possible medically…
- Trial name
- NCT01370629
- Testing
- Vernakalant
- Where
- 6 sites in Austria, Denmark and 4 more
- Volunteers
- 2,015 people
- Sponsor
- Correvio International Sarl
Atrial Fibrillation
Dual Versus Single Shock for Cardioversion of Atrial Fibrillation
The investigators aim to investigate the immediate success rate (rate of termination of atrial fibrillation) of dual shock cardioversion compared with standard single shock cardioversion in patients with baseline characteristics…
- Trial name
- NCT03943693
- Testing
- Double shock, Single shock
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Oklahoma
New Onset Atrial Fibrillation, Sepsis
Rapid Atrial Fibrillation Treatment Strategy
Prospective, randomized, open-label clinical trial studying the treatment of new onset atrial fibrillation in critically ill patients with septic shock.
- Conditions
- New Onset Atrial Fibrillation, Sepsis, Respiratory Failure
- Trial name
- RAFTS (NCT04092621)
- Testing
- Amiodarone in Parenteral Dosage Form, Amiodarone Pill, Direct Current Cardioversion (DCC)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Our Lady of the Lake Hospital
Cardioversion, Atrial Fibrillation
MAX - SHOCK Clinical Trial
Can Electrical Cardioversion (ECV) for AF be improved. It is the preferred method to restore sinus rhythm in patients with AF in whom a rhythm-control strategy is pursued.
- Trial name
- MAX-SHOCK (NCT06556667)
- Testing
- biphasic defibrillator with maximum energy of 200J (® Zoll), biphasic defibrillator with maximum energy of 360J (® Physio-Control)
- Where
- Canada
- Volunteers
- 376 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Atrial Fibrillation
Heart Rhythm Changes in Patients With Atrial Fibrillation After Cardiopulmonary Bypass: a Retrospective Analysis
The goal of this observational study is to learn about the lthe effect of the tetralogy of medication regimen on intraoperative cardioversion in patients with persistent AF.
- Trial name
- NCT06553391
- Testing
- The tetralogy of medication regimen
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Atrial Fibrillation
Predictors for Recurrence of Atrial Fibrillation After Electrical Cardioversion
In patients with persistent atrial fibrillation (AF), electrical cardioversion is very effective in restoring sinus rhythm if modern, biphasic cardioverters are used.
- Trial name
- PRE-ELECTRIC (NCT03346863)
- Where
- Norway
- Volunteers
- 270 people
- Sponsor
- Vestre Viken Hospital Trust
Atrial Fibrillation
Validation Study of Pulse Wave Velocity and Augmentation Index in Atrial Fibrillation
This study aims to evaluate the reliability of measurements of arterial stiffness (pulse wave velocity (PWV), pulse wave contour analysis (PWA), central augmentation index (AIx) and pulse pressure (PP)) in atrial fibrillation…
- Trial name
- NCT02754349
- Testing
- SphygmoCor version 7, AtCor Medical, Sydney, Australia
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- Onze Lieve Vrouw Hospital
Atrial Fibrillation, Paroxysmal or Persistent
The SAFE Prospective Registry
Secretoneurin (SN) is a neuropeptide from the chromogranin family that influences intracellular calcium handling. SN suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor.
- Trial name
- NCT05794464
- Testing
- Catheter ablation and/or electrical cardioversion
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- University Hospital Ostrava
Atrial Fibrillation
Intravenous Magnesium Infusion in Patients Undergoing Cardioversion of Atrial Fibrillation Trial
The proposed study is designed to evaluate the effect of an intravenous infusion of magnesium sulfate in facilitating successful cardioversion of atrial fibrillation and in decreasing the energy threshold (in J) required for…
- Trial name
- MICA (NCT01597557)
- Testing
- Magnesium Sulfate
- Where
- United States
- Volunteers
- 261 people
- Sponsor
- State University of New York at Buffalo
Atrial Fibrillation
QOL Improvement After Cardioversion of Persistent AF (QOL-CAFRCT)
Atrial fibrillation (AF) is a type of irregular heart rhythm due to electrical signal disturbances of the heart. It is a very common arrhythmia and the risk of developing AF increases with age and with other risk factors such as…
- Trial name
- QOL-CAFRCT (NCT05136131)
- Testing
- Electrical cardioversion
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Out-Of-Hospital Cardiac Arrest, Ventricular Fibrillation
Real Time Amplitude Spectrum Area to Guide Defibrillation
AMSA trial is a multicenter, randomized, controlled study in out-of-hospital cardiac arrest patients. The purpose of the study is to test the hypothesis that a real time AMSA analysis during CPR may predict the success of…
- Trial name
- AMSA (NCT03237910)
- Testing
- AMSA, Defibrillation, CPR
- Where
- 2 sites in Italy
- Volunteers
- 31 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Atrial Fibrillation
Shock Energy for Electrical Cardioversion of Persistent Atrial Fibrillation
The goal of this clinical trial is to compare the efficacy of a maximum output shock for cardioverting atrial fibrillation between two commonly used defibrillators in New Zealand .
- Trial name
- NCT05903170
- Testing
- 360J LifePak Monitor/Defibrillator, 200J Philips HeartStart MRx Monitor/Defibrillator
- Where
- New Zealand
- Volunteers
- 100 people
- Sponsor
- Wellington Hospital
Atrial Fibrillation
Impact of New Biomarkers on Maintenance of Sinus Rhythm After Cardioversion or Ablation of Atrial Fibrillation
The Biorhythm study aims to investigate the utility of new biomarkers (e.g. MR proANP, ST2) measured pre-procedure for the prediction of procedural success in patients with atrial fibrillation undergoing cardioversion or ablation.
- Trial name
- Biorhythm (NCT03351816)
- Testing
- Ablation of atrial fibrillation, Cardioversion
- Where
- 3 sites in France
- Volunteers
- 106 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Atrial Fibrillation
Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)
The purpose of this study is to compare edoxaban to warfarin (with enoxaparin, if needed). It will see if edoxaban prevents stroke and other blood clotting problems as well and as safely as warfarin.
- Trial name
- ENSURE-AF (NCT02072434)
- Testing
- Edoxaban, Warfarin, Enoxaparin
- Where
- 228 sites in United States, Austria and 17 more
- Volunteers
- 2,199 people
- Sponsor
- Daiichi Sankyo
Atrial Fibrillation
Evaluation of Abbreviated Versus Conventional Course of Dabigatran Etexilate Before Electric Cardioversion in Patients With Atrial Fibrillation (RE-SOUND Study)
The purpose of the study is to evaluate the efficacy of abbreviated 3-day anticoagulation with dabigatran etexilate before cardioversion guided by trans-oesophageal echocardiography in comparison with conventional 3- week course…
- Trial name
- RE-SOUND (NCT03975062)
- Testing
- dabigatran etexilate
- Where
- Russia
- Volunteers
- 400 people
- Sponsor
- Ural State Medical University